BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  Medpace Holdings, Inc. Reports Third Quarter 2017 Results

  Net service revenue for the three months ended September 30, 2017 was $98.7 million, an increase of 4.1%, compared to $94.8 million for the comparable prior-year period.

  October 30, 2017

   · 

  24 min read
• Merck KGaA Release: New Data Analyses at ECTRIMS Highlight Benefit-Risk Profile of Investigational Cladribine Tablets in Relapsing Multiple Sclerosis

  Merck KGaA announced new benefit-risk data for investigational Cladribine Tablets, for the treatment of relapsing multiple sclerosis (MS), at MSParis2017 in Paris, France.

  October 30, 2017

   · 

  10 min read
• Deals

  PDL BioPharma Issues Statement in Response to Neos Therapeutics Rejection of PDL Acquisition Proposal

  PDL BioPharma today issued the following statement in response to the Neos Board of Directors’ rejection of PDL’s October 26 proposal to acquire Neos for $10.25 per share in cash.

  October 30, 2017

   · 

  2 min read
• Business

  Theradiag Release: Revenues at the End of September 30, 2017

  During the period to September 30, 2017, Theradiag generated consolidated revenues of €6.8 million, up +7% compared with 2016.

  October 30, 2017

   · 

  2 min read
• Pharnext Announces Acceptance of Late Breaking Abstract at the 10th Clinical Trials on Alzheimer’s Disease Conference

  Pharnext announced that new synergy data related to PXT864, the Company’s second lead PLEODRUG in development for the treatment of Alzheimer’s disease (AD), will be presented as a late breaking poster at the 10th Clinical Trials on Alzheimer’s Disease Conference.

  October 30, 2017

   · 

  3 min read
• Business

  Mustang Bio Establishes CAR T Cell Therapy Manufacturing Facility in Massachusetts

  The facility is expected to be operational for the production of personalized CAR T therapies in 2018.

  October 30, 2017

   · 

  4 min read
• 

  Deals

  Xynomic Pharma to Fork Over $502M for Boehringer Ingelheim’s Novel RAF Inhibitor

  Under the terms of the agreement Xynomic will pay upfront, milestone and royalty payments up to approximately $502M.

  October 30, 2017

   · 

  2 min read
• Mauna Kea Technologies: New CONTACT Study Analysis Demonstrates Cellvizio’s Ability to Improve the Management of Patients With Pancreatic Cysts

  Mauna Kea Technologies announced that Cellvizio was featured in several presentations at the United European Gastroenterology Week (UEGW) 2017 meeting, including a late-breaking presentation of new data from the CONTACT study of Cellvizio for the diagnosis of pancreatic cysts.

  October 30, 2017

   · 

  5 min read
• Drug Development

  Anavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference

  ANAVEX2-73 has shown to have neurorestorative effects in a model for experimental parkinsonism.

  October 30, 2017

   · 

  5 min read
• 

  Abbott Shows off Landmark XIENCE Stent Data

  The data was presented during a late-breaking session at the 29th Transcatheter Cardiovascular Therapeutics meeting.

  October 30, 2017

   · 

  4 min read